Académique Documents
Professionnel Documents
Culture Documents
S ( O&G )
I st YEAR PG
Endometriosis
Endometriosis is a disease in which
the pelvis
Features of
Endometriosis
Prevalence 2-50% of women; 21-47% of
infertility cases
Exposure to ovarian hormones appears to
be essential
No known racial or socioeconomic
predilection
Severe disease may occur in families
Is Endometriosis
Increasing?
1965-1984, endometriosis rose from 10 to
19% as primary indication for hysterectomy
Simultaneously, a trend of more conservative
Normal Pelvic
Structures
DrMonaShroff
www.obgyntoday.info
ENDOMETRIOSIS
- Pelvic
- Extra pelvic
Umbilicus.
Scars (Lap.).
Lungs & plura.
Others.
DrMonaShroff
www.obgyntoday.info
Etiology: Theories
Sampson: Retrograde Menstruation
Hematologic Spread
Lymphatic Spread
Coelomic Metaplasia
Genetic Factors
Immune Factors
Combination of the Above
No Single Theory Explains All Cases of
Endometriosis
Etiologies of
Endometriosis
Sampson's theory: Retrograde menses and
peritoneal implantation
sites
Immunogenic defect
Diagnosis
Laparoscopy (Gold Standard)
Laparotomy
Inconclusive: CA-125, Pelvic Exam, History,
Imaging Studies
Biopsy Preferable Over Visual Inspection
Appearance
Endometriosis May Appear
Brown
Black (Powderburn)
Clear (Atypical)
Endometriosis May Be Associated with
Peritoneal Windows
DrMonaShroff
www.obgyntoday.info
DrMonaShroff
www.obgyntoday.info
Treatment: Overall
Approach
Recognize Goals:
Pain Management
Preservation / Restoration of Fertility
Discuss with Patient:
Disease may be Chronic and Not Curable
Optimal Treatment Unproven or Nonexistent
Treatment :
Consideration
Age.
Symptoms.
Stage.
Infertility.
Classification / Staging
Several Proposed Schemes
Revised AFS System: Most Often Used
Ranges from Stage I (Minimal) to Stage IV
(Severe)
Staging Involves Location and Depth of
Disease, Extent of Adhesions
DrMonaShroff
www.obgyntoday.info
DrMonaShroff
www.obgyntoday.info
NSAIDs
OCPs (Continuous)
Progestins
Danazol
GnRH-a
GnRH-a + Add-Back Therapy
Aromatase Inhibitors
Misc: Opoids, SSRIs
Indications of
Hormonal Rx
1. Small endometriotic; lesions.
2. Recurrence after conservative
surgery.
3. Preoperative for 6-12 weeks to
decrease size.
4. Postoperative for residual lesions.
5. When operation is contraindicated
or refused by the patient.
or
2. Progestins (to avoid oestrogen's side effects medroxy
progesterone acetate Depo medroxy progesterone
acetate (DMPA) can be given in a dose of 150 mg IM
every I - 3 months .
Continuous OCPs
Pseudopregnancy (Kistner)
? Minimizes Retrograde Menstruation
Lower Fertility Rates than Other Medical
Treatments
Choose OCPs with Least Estrogenic Effects,
Maximal Androgenic / Progestin Effects
Progestins
May be as Effective as GnRH-a for Pain Control
MPA 10-30 mg/day, DP 150 mg Semi-Monthly
May be Taken Long-Term
Relatively Inexpensive
Side-Effects: AUB, Mood Swings, Weight Gain,
Amenorrhea
Danazol
Weak Androgen
Suppresses LH / FSH
Causes Endometrial Regression, Atrophy
Expensive
Side-Effects: Weight Gain, Masculinization,
GnRH-a
(Leuprolide,triptorelin)
Initially Stimulate FSH / LH Release
Down-Regulates GnRH
ReceptorsPseudomenopause
Long-Term Success Varies
Expensive
Use Limited by Hypoestrogenic Effects
May be Combined with Add-Back (? >1 Year )
Aromatase Inhibitors
Blocking the aromatase activity in
Gestrinone
It is a synthetic 19 Nor steroid exhibits
marked and - progcs-terogenic and anti oestrogenic as well as mild androgenic and
anti -gonadotrophic properties .
The endocrine effects of Gestrinone are
similar to those of Danazol which leads
mainly to inhibition of ovarian
steroidogenesis .
The dose is 2.5 - 5 mg orally twice weekly .
Surgical Treatment
(Laparoscopy / Laparotomy)
/
Conclusion
Endometriosis is a Common, Chronic Disease
Typical Symptoms Include Pain, Infertility,
THANK YOU
DrMonaShroff
www.obgyntoday.info